Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
Sponsor: Children's Mercy Hospital Kansas City
Summary
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
Official title: Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy
Key Details
Gender
All
Age Range
5 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-10-15
Completion Date
2029-12-31
Last Updated
2025-07-18
Healthy Volunteers
No
Conditions
Interventions
Trihexyphenidyl
6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
Locations (1)
Children's Mercy Hospital Kansas City
Kansas City, Missouri, United States